ASSIGNMENT AND AMENDMENT NO. 2 OF SEED BANK SUPPLY AGREEMENTSeed Bank Supply Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Assignment and Amendment No. 2 of Seed Bank Supply Agreement (“Assignment”), effective as of January 6, 2021 (“Assignment Effective Date”), is entered into by and among Hadasit Medical Research Services and Development Ltd., a company duly incorporated under the laws of Israel (“Hadasit”), Oscine Corp., a Delaware corporation (“Oscine”), and Sana Biotechnology, Inc., a Delaware corporation (“Sana”).
AMENDMENT NO. 1 TO SEED BANK SUPPLY AGREEMENTSeed Bank Supply Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Seed Bank Supply Agreement (“Amendment No. 1”), effective as of the Amendment No. 1 Effective Date (defined in paragraph 1 below), is entered into by and between Oscine Corp., a Delaware corporation (“Oscine”), Hadasit Medical Research Services and Development Ltd., a company duly incorporated under the laws of Israel (“Hadasit”) and, solely for the purposes of Section 4 hereof, Sana Biotechnology, Inc., a Delaware corporation (“Sana”). Capitalized terms not otherwise defined herein shall have the meaning set forth in the Original Agreement.
Seed Bank Supply AgreementSeed Bank Supply Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This Seed Bank Supply Agreement (this “Agreement”) is made and entered into as of July 9, 2018 (the “Effective Date”), by and between Hadasit Medical Research Services and Development Ltd., a company duly incorporated under the laws of Israel (“Hadasit”) and Oscine Therapeutics (U.S.) Inc. (“Oscine”) (Hadasit and Oscine shall each be referred to as a “Party” and jointly as the “Parties”).
